The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Enanta Pharmaceuticals Inc shares valued at $256,050 were purchased by Luly Jay R. on Feb 12 ’25. At $5.69 per share, Luly Jay R. acquired 45,000 shares. The insider’s holdings grew to 846,638 shares worth approximately $6.68 million following the completion of this transaction.
Also, Kieffer Tara Lynn sold 2,283 shares, netting a total of over 18,401 in proceeds. Following the sale of shares at $8.06 each, the insider now holds 29,305 shares.
Before that, Luu Brendan had sold 2,283 shares from its account. In a trade valued at $18,401, the Chief Business Officer traded Enanta Pharmaceuticals Inc shares for $8.06 each. Upon closing the transaction, the insider’s holdings decreased to 2,283 shares, worth approximately $0.28 million.
As published in a research note from JP Morgan on August 09, 2023, Enanta Pharmaceuticals Inc [ENTA] has been rated down from a Neutral to an Underweight and the price target has been revised to $14. Analysts at Jefferies downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in early August. As of December 09, 2022, H.C. Wainwright has initiated its “Buy” rating for ENTA. Earlier on July 06, 2022, Evercore ISI upgraded its rating. Their new recommendation was “an Outperform” for ENTA stock which previously was a “an In-line”.
Analyzing ENTA Stock Performance
On last trading session, Enanta Pharmaceuticals Inc [NASDAQ: ENTA] plunged -1.00% to $7.89. The stock’s lowest price that day was $7.73, but it reached a high of $8.03 in the same session. During the last five days, there has been a surge of approximately 5.06%. Over the course of the year, Enanta Pharmaceuticals Inc shares have dropped approximately -39.63%. Shares of the company reached a 52-week high of $8.76 on 02/24/25 and a 52-week low of $4.09 on 04/09/25.
Support And Resistance Levels for Enanta Pharmaceuticals Inc (ENTA)
According to the 24-hour chart, there is a support level at 7.74, which, if violated, would cause prices to drop to 7.58. In the upper region, resistance lies at 8.04. The next price resistance is at 8.18. RSI (Relative Strength Index) is 67.32 on the 14-day chart, showing neutral technical sentiment.
Is Enanta Pharmaceuticals Inc subject to short interest?
Stocks of Enanta Pharmaceuticals Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.36 million shares to 2.5 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 2.85 million shares. A decline of -14.24% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 14.96 of the overall float, the days-to-cover ratio (short ratio) decline to 14.96.
Which companies own the most shares of Enanta Pharmaceuticals Inc (ENTA)?
In terms of Enanta Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 24 in the next 12 months, up nearly 201.13% from the previous closing price of $7.97. Analysts anticipate Enanta Pharmaceuticals Inc stock to reach 24 by 2025, with the lowest price target being 24. In spite of this, 3 analysts ranked Enanta Pharmaceuticals Inc stock as Buy at the end of 2025. On June 01, 2022, Evercore ISI assigned a price target of “an In-line” to the stock and upgraded coverage with a $39.
